A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi®
NCT03803748 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96
Last updated 2022-12-23
Summary
SIFI SpA had developed Eyestil Plus®. It is sterile eyedrops without preservatives with a physiological pH containing sodium hyaluronate. Its intended purpose is to moisturize, lubricate and protect the ocular surface and gives temporary relief to burning, irritation and dry eye-related discomfort, and other complaints induced, for example, by: prolonged use of either soft, semi rigid or rigid contact lenses; exposure to environmental factors (air conditioning, exposure to solar radiation, wind, smoke, pollution, severe climatic conditions, dust); ocular fatigue caused by studying, working, driving or prolonged exposure to electronic devices.
Eyestil Plus® is CE marked but not available yet in all European countries. Considering the European regulatory change on medical devices - from a Directive (Directive 1993/42/EEC) to a Regulation (MDR 2017/745) that now requires clinical evidence of device performance and safety; SIFI Spa decided to implement the present clinical comparative performance study. The choice of Vismed Multi® as the comparator has been done since it is the current French standard of care treatment for patients with moderate to severe dry eyes.
Conditions
- Dry Eye Syndromes
Interventions
- DEVICE
-
Eyestil Plus®
• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
Sponsors & Collaborators
-
SIFI SpA
lead INDUSTRY
Principal Investigators
-
Pierre Jean Pisella, MD, Pr · HOPITAL BRETONNEAU
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-07-17
- Primary Completion
- 2022-05-02
- Completion
- 2022-08-31
Countries
- France
- Spain
Study Locations
More Related Trials
-
Clinical Investigation on the Use of Ophthalmic Solution Based on Sodium Hyaluronate in Treatment of Eye Discomfort
NCT05777798 ·Status: COMPLETED
-
Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness
NCT03645850 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye
NCT02975102 ·Status: COMPLETED ·Phase: NA
-
Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms
NCT00938704 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis
NCT05733624 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects
NCT02380248 ·Status: COMPLETED ·Phase: NA
-
A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study
NCT07234318 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
NCT04393441 ·Status: COMPLETED ·Phase: PHASE3
-
Performance and Safety of T2769 in DED
NCT05965778 ·Status: COMPLETED ·Phase: NA
-
A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
NCT02117687 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness
NCT03517748 ·Status: COMPLETED ·Phase: NA
-
Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease
NCT03492541 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease
NCT05865379 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
NCT01541891 ·Status: COMPLETED ·Phase: PHASE2
-
HU007 in Patients with Dry Eye Syndrome
NCT05743764 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye
NCT01657253 ·Status: COMPLETED ·Phase: PHASE3
-
Study on Prevention and Treatment of Dry Eye in Patients Using Glaucoma Drops
NCT03515187 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
NCT06660290 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects
NCT03524157 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
NCT01240382 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
NCT02023268 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial for the Evaluation of Safety and Efficacy of Drop 0.4%
NCT06985875 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease
NCT05865457 ·Status: RECRUITING ·Phase: NA
-
HU007 Eye Drops in Patients With Dry Eye Syndrome
NCT04384991 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye
NCT01791426 ·Status: WITHDRAWN ·Phase: NA